This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Aptevo Therapeutics appoints Mary Janatpour
Business executive appointment

Aptevo Therapeutics appoints Mary Janatpour

Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The appointment of Mary J. Janatpour>>> as Chief Scientific Officer at Aptevo Therapeutics>>> is viewed positively, as her extensive experience in oncology R&D is expected to accelerate the company's pipeline development, potentially boosting investor confidence in Aptevo Therapeutics>>>'s future growth and stock performance. This strategic hire could enhance the company's ability to bring novel cancer treatments to market, impacting the biotechnology sector.

biotechnology pharmaceuticals
Event Summary

Aptevo Therapeutics>>> announced the appointment of Mary J. Janatpour>>>, Ph.D., as Senior Vice President & Chief Scientific Officer. Dr. Janatpour brings over 25 years of oncology research and development leadership from various biotechnology and pharmaceutical organizations, including Institute for Medical Research, Schering-Plough Biopharma, and Chiron Corporation>>>. In her new role, she will lead Aptevo Therapeutics>>>'s research and preclinical development efforts, focusing on advancing its expanding pipeline of multispecific therapeutics and the recently announced radiopharmaceutical therapeutic collaboration with Niowave>>>. Jeff Lamothe>>>, President and CEO of Aptevo Therapeutics>>>, highlighted the importance of her leadership in executing current clinical priorities and pursuing new opportunities in cancer treatment.

Entities Involved
stock
Aptevo Therapeutics
Aptevo Therapeutics appointed Mary J. Janatpour>>> as Senior Vice President & Chief Scientific Officer, which is expected to strengthen its oncology pipeline and radiopharmaceutical development strategy.
Importance 100.0 Sentiment 40.0
per
Mary J. Janatpour
Mary J. Janatpour>>> was appointed Senior Vice President & Chief Scientific Officer of Aptevo Therapeutics>>>, bringing over 25 years of oncology R&D leadership to advance the company's pipeline.
Importance 90.0 Sentiment 50.0
per
Jeff Lamothe
Jeff Lamothe>>>, CEO of Aptevo Therapeutics>>>, commented on the strategic importance of Mary J. Janatpour>>>'s appointment for the company's pipeline expansion.
Importance 30.0 Sentiment 0.0
priv
Niowave
Niowave>>> is collaborating with Aptevo Therapeutics>>> on radiopharmaceutical therapeutics, a new direction for Aptevo Therapeutics>>>'s pipeline.
Importance 20.0 Sentiment 0.0
stock
Schering-Plough
Mary J. Janatpour>>> previously held a leadership position at Schering-Plough Biopharma, a division of Schering-Plough>>>.
Importance 10.0 Sentiment 0.0
stock
Chiron Corporation
Mary J. Janatpour>>> previously held a leadership position at Chiron Corporation>>>.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.